Please login to the form below
cost
This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.
Novartis sees five new $1bn-plus launches in next two years
He said the price would be far lower than that, but would be set at “a fraction” of the current cost of care – which is in the $4m-$5m range over ... Analysts think the eventual price will be close to $2m, while the influential Institute for
Latest news
-
NHS England wants money-back guarantee on Orkambi
Vertex has been locked in a row with England’s cost effectiveness watchdog NICE and specialist medicines budget holder NHS England for more than three years, and today both sides disclosed
-
Report shows benefits of GP at Hand digital service, but concerns too
When you consider that the average A&E visit costs £1, 602 and the average outpatient appointment £1, 252 then you can see how quickly Babylon GP at Hand and
-
Stung by critics, J&J says antidepressant Spravato saves money
Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... For its part, J&J insists its new cost-per
-
Still no breakthrough on Orkambi talks, MPs want answers
The lack of progress on Orkambi is in stark contrast to other new, high cost treatments, with NHS England announcing several major new pricing and access deals in recent weeks.
-
As Europe goes to polls, pharma seeks to keep healthcare, R&D a priority
future for European citizens, based on medical innovation, timely access to quality health interventions, better health outcomes for patients, and cost-effective healthcare.
More from news
Approximately 9 fully matching, plus 2,690 partially matching documents found.
Latest Intelligence
-
It’s not the end of the world, is it?
not claim to offer value, cost-effectiveness or some other paraphrasing of the value-based mantra. ... our industry (and indeed, any industry) offers is not the best possible value for money when considered from a strictly full-cost for full-benefit
-
Is anybody listening?
and facilitate both direct and indirect healthcare cost savings,” says Craig. ... The potential rewards are significant; peer-to-peer engagement improves outcomes and reduces the cost and burden of disease.
-
The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
And, to me, there are three. The first is that the government has threatened the industry during every recent PPRS negotiation with a reduction in the standard NICE cost-effectiveness threshold. ... the government dictates, or forcing all companies into
-
The first, my last, my everything
Well-designed solutions, particularly for complex high-cost conditions, are going beyond traditional ‘adherence’ tools and instead providing personalised programmes that add value to the patient experience.
-
The Orkambi row explained
If England were to pay this price for the approximately 2, 834 people who are eligible, it would cost around £295m, which would make it one of the country’s biggest ... April 2016: NICE’s initial rejection of Orkambi despite evidence of its efficacy,
More from intelligence
Approximately 2 fully matching, plus 430 partially matching documents found.
Latest appointments
-
Merck appoints new chief information officer
He has a proven track record in successfully managing large-scale IT transformation initiatives, as well as building cost-effective international IT organisations.”.
-
Peter Kelly named managing director of Accord Healthcare UK
We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Sandoz UK promotes Tim de Gavre to country head
As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs,
-
EY appoints global life sciences industry leader
New solutions will be required to meet the global challenges of sustainability of healthcare systems, aging populations, chronic disease and increasing cost pressures.
More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest from PMHub
-
Havas Lynx Launches Specialist Clinical Trial Recruitment Agency, Havas Lynx Faze
cost of finding patients.
-
Stephen Fry voices new Aardman animation on the shocking state of mental health worldwide
Suicide is the second leading cause of death among 15-29 year-olds worldwide, and mental ill health currently costs the world 2.5 trillion dollars per year.
-
GPs will play a pivotal role in integrated care
The NHS will fund 70 percent of the cost of most of the new roles with practices paying the rest. ... However, there is still tension between hospital procurement and primary care FP10 costs.
-
New opportunities in emerging markets
aggressive cost containment measures).
-
Event: World Pharma Pricing and Market Access Congress
There was much discussion about how these products, with their high upfront costs and inherent limitations will necessitate the creation of a new access model.
More from PMHub
Approximately 3 fully matching, plus 326 partially matching documents found.
Featured jobs
-
Midweight Brand Planner
-
Up to £50, 000
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Verily unveils next-gen trials alliance with Novartis, Pfizer
- Syncona launches another cell therapy company, Treg specialist Quell
- Keytruda monotherapy fails in triple negative breast cancer
- Moving annual total (MAT)
- Europe responding to gene therapy challenge, but picture remains fragmented
- Key success factor (KSF)
PMHub
COUCH.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...
Latest intelligence
- Playing Mind Games
- To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
- PM Society Digital Award Finalists
- P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
- The Exhibition Hall: Past, Present and Future
- As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Quick links
Infographics
